login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
KURA ONCOLOGY INC (KURA) Stock News
USA
-
Nasdaq
- NASDAQ:KURA -
US50127T1097
-
Common Stock
11.15
USD
-0.29 (-2.53%)
Last: 12/2/2025, 10:12:03 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
KURA Latest News, Press Relases and Analysis
All
Press Releases
2 hours ago - By: Kura Oncology, Inc.
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
7 days ago - By: Kura Oncology, Inc.
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
18 days ago - By: Benzinga
Kura Scores A Big Win As FDA Approves Its New Leukemia Pill
18 days ago - By: Stocktwits
Kura Oncology Stock Ignites Retail Frenzy After FDA Clears First Daily Pill For Relapsed Leukemia Patients
19 days ago - By: Kura Oncology, Inc.
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
a month ago - By: Benzinga
- Mentions:
SEE
HRMY
FOLD
UPST
...
Earnings Scheduled For November 4, 2025
a month ago - By: Stocktwits
- Mentions:
ITOT
URTY
KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement
20 days ago - By: Kura Oncology, Inc.
Kura Oncology to Participate in Upcoming Investor Conference
25 days ago - By: Kura Oncology, Inc.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a month ago - By: Kura Oncology, Inc.
Kura Oncology Reports Third Quarter 2025 Financial Results
a month ago - By: Kura Oncology, Inc.
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
a month ago - By: Kura Oncology, Inc.
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting
4 months ago - By: The Motley Fool
Kura (KURA) Revenue Drops 61%
a month ago - By: Kura Oncology, Inc.
Kura Oncology to Report Third Quarter 2025 Financial Results
a month ago - By: Kura Oncology, Inc.
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
2 months ago - By: Kura Oncology, Inc.
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
2 months ago - By: Kura Oncology, Inc.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Kura Oncology, Inc.
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
2 months ago - By: Kura Oncology, Inc.
Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)
2 months ago - By: Kura Oncology, Inc.
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
2 months ago - By: Kura Oncology, Inc.
Kura Oncology to Participate in Upcoming Investor Conference
3 months ago - By: Kura Oncology, Inc.
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
3 months ago - By: Kura Oncology, Inc.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Kura Oncology, Inc.
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program
3 months ago - By: Kura Oncology, Inc.
Kura Oncology to Participate in Three Upcoming Investor Conferences
4 months ago - By: Zacks Investment Research
- Mentions:
ROIV
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates
4 months ago - By: Kura Oncology, Inc.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Kura Oncology, Inc.
Kura Oncology to Report Second Quarter 2025 Financial Results
Please enable JavaScript to continue using this application.